Navigation Links
Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
Date:10/28/2008

- Presentation to Be Webcast Live On Company's Website -

TUSTIN, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today announced that senior management will present at the BIO Investor Forum 2008 on Thursday, October 30, 2008 at 3:45 pm PDT (6:45 pm EDT). The conference will be held at the Palace Hotel in San Francisco.

A live webcast and archived replay of the company's presentation will be available at the Investor Relations section of Peregrine's website at http://www.peregrineinc.com.

For more information about this conference, please visit: http://investorforum.bio.org/opencms/bif/2008/

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and serious virus infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio- manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Contacts
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
2. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
3. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
4. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
5. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
6. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
7. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
8. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
9. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
10. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
11. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... the ultimate memory device for computing may have just ... College of New York led by chemist Stephen O,Brien ... and ferroelectric properties. , Combining both properties is very ... them and for the devices that might ultimately be ... properties in a single material, however, has proved difficult ...
(Date:9/17/2014)... -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) was ... Young LLP ("EY") that it was resigning effective September 11, ... the Company on September 15, 2014 and reported in PDL,s ... PDL has issued the following statement in response to the ... on the reason for the resignation of EY.  We were ...
(Date:9/17/2014)... DIEGO and PRINCETON, N.J. ... (NASDAQ: OTCQB:AEMD), the pioneer in developing targeted therapeutic devices ... and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), disclosed ... 2014 Exosomes & SingleCell Analysis Summit. On ... Exosome Sciences will give a presentation entitled: "Exosomes: A ...
(Date:9/17/2014)... NEWTOWN, Pa. , Sept. 17, 2014 ... services and eClinical Solutions, today announced three of its ... Conference for Clinical Data Management to be held ... Vegas, Nevada . The Company also announced the ... to raise overall quality in clinical trials acquired earlier ...
Breaking Biology Technology:Oxides discovered by CCNY team could advance memory devices 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 3Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 2Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 3BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3
... broad corporate changes are ... ... Board: AVNA) today reported financial results for its first,quarter ended March ... Company refocused its business model from managing the,development of a portfolio ...
... Technology Distributors ... 2007., PLEASANTON, Calif., May 19 Direct Medical ... distribution network covering all,of Russia. This partnership has resulted ... volume sales to a number of medical,providers in Russia., ...
... W. Freston Single Topic Conference Series for ... Gastroenterology ... (AGA) Foundation for Digestive Health and Nutrition (FDHN),announced a gift ... Fund within the AGA Foundation,s overall endowment.,Interest earned from The ...
Cached Biology Technology:Advance Nanotech Reports First Quarter 2008 Financial Results 2Advance Nanotech Reports First Quarter 2008 Financial Results 3Advance Nanotech Reports First Quarter 2008 Financial Results 4Advance Nanotech Reports First Quarter 2008 Financial Results 5Advance Nanotech Reports First Quarter 2008 Financial Results 6Advance Nanotech Reports First Quarter 2008 Financial Results 7Advance Nanotech Reports First Quarter 2008 Financial Results 8Advance Nanotech Reports First Quarter 2008 Financial Results 9Advance Nanotech Reports First Quarter 2008 Financial Results 10Direct Medical Systems Reaches Profitability in 2-1/2 Years, as a Result of Sales of the World's Smallest and Lightest Ultrasound System, the InNovaSound USB Ultrasound. 2Takeda Pharmaceuticals Establishes $3 Million Endowment with AGA Foundation 2Takeda Pharmaceuticals Establishes $3 Million Endowment with AGA Foundation 3Takeda Pharmaceuticals Establishes $3 Million Endowment with AGA Foundation 4
(Date:9/18/2014)... people are too stressed they are often grouchy, grumpy, ... Institute (BMI) at EPFL have just highlighted a fundamental ... and the loss of social skills and cognitive impairment. ... regulatory molecule in the brain. This was revealed by ... , Carmen Sandi,s team went to look for answers ...
(Date:9/18/2014)... the ideal animal in which to study the genes ... into tens of thousands of freshwater streams and lakes ... adapt to the new environment. , Breeding studies between ... up one of the genes that controls tooth number, ... regulation in a freshwater population is associated with a ...
(Date:9/18/2014)... invisible is probably the ultimate form of camouflage: you ... And this strategy is not as uncommon as you ... Baltimore County, USA, explains that the larval life stages ... one part of the anatomy that most creatures cannot ... eyes have to shield each individual eye unit with ...
Breaking Biology News(10 mins):How stress tears us apart 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3Transparent larvae hide opaque eyes behind reflections 2
... five times as likely as U.S-born children to suffer from ... Health Department study, and the risk is highest among the ... lead poisoning in 2002, published online in the American Journal ... lived abroad within the previous six months were 11 times ...
... WASHINGTON, DECEMBER 19, 2007 - The National Fish ... grant to the Manomet Center for Conservation Sciences ... programs that address the decline of shorebird populations ... will be conducted by the Western Hemisphere Shorebird ...
... rattlesnake skin and smear it on their fur to ... study by researchers at UC Davis. Barbara Clucas, ... observed ground squirrels (Spermophilus beecheyi) and rock squirrels (Spermophilus ... pieces of shed snakeskin, chewing it and then licking ...
Cached Biology News:Study shows immigrant children are at increased risk of lead poisoning 2Study shows immigrant children are at increased risk of lead poisoning 3Manomet Center awarded major NFWF grant to foster shorebird conservation 2Manomet Center awarded major NFWF grant to foster shorebird conservation 3
Request Info...
... Bean Nuclease catalyzes the degradation of single-stranded ... terminated products. While the nuclease prefers ssDNA ... concentrations the enzyme degrades double-stranded DNA from ... been used for transcript mapping studies (3,4), ...
... fosmid (40kb), and large plasmid insert (10-20kb) ... BAC vector. On command 20-50 fold copy ... DNA purification. Available with blue-white screening (pEZ ... the highest insert stability. Kits include electrocompetent ...
...
Biology Products: